References
- Modesto C, Antón J, Rodriguez B, et al. Incidence and prevalence of juvenile idiopathic arthritis in Catalonia (Spain). Scand J Rheumatol. 2010;39(6):472–479. doi:10.3109/03009741003742722
- Pruunsild C, Uibo K, Liivamägi H, Tarraste S, Talvik T, Pelkonen P. Incidence of juvenile idiopathic arthritis in children in Estonia: a prospective population-based study. Scand J Rheumatol. 2007;36(1):7–13. doi:10.1080/03009740601089259
- Berntson L, Andersson Gäre B, Fasth A, et al. Incidence of juvenile idiopathic arthritis in the Nordic countries. A population based study with special reference to the validity of the ILAR and EULAR criteria. J Rheumatol. 2003;30(10):2275–2282.
- Thierry S, Fautrel B, Lemelle I, Guillemin F. Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine. 2014;81(2):112–117. doi:10.1016/j.jbspin.2013.09.003
- Spiegel LR, Schneider R, Lang BA, et al. Early predictors of poor functional outcome in systemic‐onset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum off J Am Coll Rheumatol. 2000;43(11):2402–2409. doi:10.1002/1529-0131(200011)43:11<2402::AID-ANR5>3.0.CO;2-C
- Bowyer SL, Roettcher PA, Higgins GC, et al. Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis. J Rheumatol. 2003;30(2):394–400.
- Svantesson H, Akesson A, Eberhardt K, Elborgh R. Prognosis in juvenile rheumatoid arthritis with systemic onset a follow-up study. Scand J Rheumatol. 1983;12(2):139–144. doi:10.3109/03009748309102900
- Deslandre J. Systemic-onset juvenile idiopathic arthritis; 2007. Available from: https://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=11711&Disease_Disease_Search_diseaseGroup=Still-disease&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Systemic-onset-juvenile-idiopathic-arthritis&title=Systemic-onset%20juvenile%20idiopathic%20arthritis&search=Disease_Search_Simple. Accessed April 14, 2019.
- Modica RF, Lomax KG, Batzel P, Cassanas A. Impact of systemic juvenile idiopathic arthritis/Still’s disease on adolescents as evidenced through social media posts. Open Access Rheumatol Res Rev. 2018;10:73–81.
- Bruck N, Schnabel A, Hedrich CM. Current understanding of the pathophysiology of systemic juvenile idiopathic arthritis (sJIA) and target-directed therapeutic approaches. Clin Immunol. 2015;159(1):72–83. doi:10.1016/j.clim.2015.04.018
- Leek AP, Anton J, Avcin T, et al. The SHARE recommendations on diagnosis and treatment of systemic JIA; 2020. Available from: https://acrabstracts.org/abstract/the-share-recommendations-on-diagnosis-and-treatment-of-systemic-jia/. Accessed October 28, 2020.
- Bracaglia C, Prencipe G, De Benedetti F. Macrophage activation syndrome: different mechanisms leading to a one clinical syndrome. Pediatr Rheumatol Online J. 2017;15(1):5. doi:10.1186/s12969-016-0130-4
- Ruscitti P, Rago C, Breda L, et al. Macrophage activation syndrome in Still’s disease: analysis of clinical characteristics and survival in paediatric and adult patients. Clin Rheumatol. 2017;36(12):2839–2845. doi:10.1007/s10067-017-3830-3
- Woo P, Southwood TR, Prieur AM, et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 2000;43(8):1849–1857. doi:10.1002/1529-0131(200008)43:8<1849::AID-ANR22>3.0.CO;2-F
- Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70(5):747–754. doi:10.1136/ard.2010.134254
- Ilowite N, Porras O, Reiff A, et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol. 2009;28(2):129–137. doi:10.1007/s10067-008-0995-9
- Nordström D, Knight A, Luukkainen R, et al. Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still’s disease. An open, randomized, multicenter study. J Rheumatol. 2012;39(10):2008–2011. doi:10.3899/jrheum.111549
- Verbsky JW, White AJ. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2004;31(10):2071–2075.
- De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385–2395. doi:10.1056/NEJMoa1112802
- Swedish Orphan Biovitrum AB. Summary of product characteristics: anakinra (Kineret); 2020. Available from: https://www.ema.europa.eu/en/documents/product-information/kineret-epar-product-information_en.pdf. Accessed August 17, 2021.
- Ter Haar NM, van Dijkhuizen EHP, Swart JF, et al. Treatment to target using recombinant interleukin-1 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five-year follow-up study. Arthritis Rheumatol Hoboken NJ. 2019;71(7):1163–1173. doi:10.1002/art.40865
- Vastert SJ, de Jager W, Noordman BJ, et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheumatol. 2014;66(4):1034–1043. doi:10.1002/art.38296
- Rossi MN, Pardeo M, Marafon DP, Sacco E, Passarelli C. Early treatment and IL1RN single nucleotide polymorphisms affect response to anakinra in systemic juvenile idiopathic arthritis. ACR Meeting Abstracts; 2019. Available from: https://acrabstracts.org/abstract/early-treatment-and-il1rn-single-nucleotide-polymorphisms-affect-response-to-anakinra-in-systemic-juvenile-idiopathic-arthritis/. Accessed October 28, 2020.
- Pardeo M, Pires Marafon D, Insalaco A, et al. Anakinra in systemic juvenile idiopathic arthritis: a single-center experience. J Rheumatol. 2015;42(8):1523–1527. doi:10.3899/jrheum.141567
- Pardeo M, Rossi MN, Marafon DP, et al. Early treatment and IL1RN SNPs affect response to anakinra in systemic juvenile idiopathic arthritis - author copy provided pre-publication; 2020.
- Richtlijn NVK. Juveniele idiopathische artritis, medicamenteuze behandeling van kinderen met; 2018. Available from: https://www.nvk.nl/themas/kwaliteit/richtlijnen/richtlijn?componentid=7864339&tagtitles=Infectieziekten+en+Immunologie,Intensive+Care,Maag-Darm-Leverziekten+(MDL),Reumatologie,Sociale+en+Psychosociale+kindergeneeskunde,Chirurgie. Accessed April 14, 2021.
- Schanberg L, Nigrovic P, Cooper A, et al., Double-blind, placebo-controlled study of anakinra in pediatric and adult patients with still’s disease. ACR Meeting Abstracts; 2020. Available from: https://acrabstracts.org/abstract/a-randomized-double-blind-placebo-controlled-study-of-anakinra-in-pediatric-and-adult-patients-with-stills-disease/. Accessed April 14, 2021.
- Nigrovic PA. Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis? Arthritis Rheumatol. 2014;66(6):1405–1413. doi:10.1002/art.38615
- Pardeo M, Bracaglia C, Tulone A, et al. Early treatment with anakinra in systemic juvenile idiopathic arthritis. ACR Meeting Abstracts; 2019. Available from: https://acrabstracts.org/abstract/early-treatment-with-anakinra-in-systemic-juvenile-idiopathic-arthritis/. Accessed February 5, 2020.
- National Institute for Health and Care Excellence (NICE). Tocilizumab for the treatment of systemic juvenile idiopathic arthritis: technology appraisal guidance [TA238]; 2011. Available from: https://www.nice.org.uk/guidance/ta238. Accessed April 14, 2019.
- National Institute for Health and Care Excellence (NICE). Anakinra for treating Still’s disease: technology appraisal guidance [TA685]; 2021. Available from: https://www.nice.org.uk/guidance/ta685. Accessed April 14, 2021.
- England NHS. Clinical commissioning policy statement: biologic therapies for the treatment of juvenile idiopathic arthritis (JIA) (E03X04). London: NHS England; 2015. Available from: https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/10/e03pd-bio-therapies-jia-oct15.pdf. Accessed August 17, 2021.
- Grevich S, Shenoi S. Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition. Adolesc Health Med Ther. 2017;8:125.
- Hakkaart-van Roijen L, Van der Linden N, Bouwmans C, Kanters T, Tann S Costing manual: methodology of costing research and reference prices for economic evaluations in healthcare; 2015. Available from: https://www.imta.nl/costingtool/. Accessed October 31, 2020.
- Z-Index BV. G-Standaard, the Dutch drug database; 2020. Available from: https://www.z-index.nl/english. Accessed June 19, 2020.
- Grom AA, Ilowite NT, Pascual V, et al. Rate and clinical presentation of macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with canakinumab. Arthritis Rheumatol. 2016;68(1):218–228. doi:10.1002/art.39407
- Ferrara G, Petrillo MG, Giani T, et al. Clinical use and molecular action of corticosteroids in the pediatric age. Int J Mol Sci. 2019;20(2):444. doi:10.3390/ijms20020444
- Kittiratchakool N, Kulpokin D, Chanjam C, et al. Cost–utility and budget impact analysis of tocilizumab for the treatment of refractory systemic juvenile idiopathic arthritis in Thailand. BMJ Open. 2020;10(9):e037588. doi:10.1136/bmjopen-2020-037588
- Boyarchuk O, Kovalchuk T, Kovalchuk N, Chubata O. Clinical variability of the systemic juvenile idiopathic arthritis course: literature review based on case series. Reumatologia. 2020;58(6):436–443. doi:10.5114/reum.2020.102010
- Giancane G, Minoia F, Davì S, Bracciolini G, Consolaro A, Ravelli A. IL-1 inhibition in systemic juvenile idiopathic arthritis. Front Pharmacol. 2016;7:467. doi:10.3389/fphar.2016.00467
- Vastert SJ, Jamilloux Y, Quartier P, et al. Anakinra in children and adults with Still’s disease. Rheumatology. 2019;58(Supplement_6):vi9–22. doi:10.1093/rheumatology/kez350
- Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63(2):545–555. doi:10.1002/art.30128
- Woerner A, Uettwiller F, Melki I, et al. Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent. RMD Open. 2015;1(1):e000036. doi:10.1136/rmdopen-2014-000036